SECONDARY HYPERPARATHYROIDISM
Clinical trials for SECONDARY HYPERPARATHYROIDISM explained in plain language.
Never miss a new study
Get alerted when new SECONDARY HYPERPARATHYROIDISM trials appear
Sign up with your email to follow new studies for SECONDARY HYPERPARATHYROIDISM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for dialysis patients with common hormone imbalance
Disease control CompletedThis study tested whether a drug called PLS240 could safely and effectively treat a hormone disorder called secondary hyperparathyroidism in people with kidney failure who are on dialysis. For the first 27 weeks, 412 participants were randomly assigned to receive either the drug …
Matched conditions: SECONDARY HYPERPARATHYROIDISM
Phase: PHASE3 • Sponsor: Pathalys Pharma • Aim: Disease control
Last updated Apr 04, 2026 00:20 UTC
-
New hope for dialysis patients: drug aims to tame dangerous hormone imbalance
Disease control CompletedThis study tested a drug called PLS240 for people with end-stage kidney disease on dialysis who also have a hormone imbalance called secondary hyperparathyroidism. The goal was to see if PLS240 could safely and effectively lower high levels of a specific hormone. In the first par…
Matched conditions: SECONDARY HYPERPARATHYROIDISM
Phase: PHASE3 • Sponsor: Pathalys Pharma • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New drug shows promise for dialysis Patients' hormone imbalance
Disease control CompletedThis study tested whether a new drug called SHR6508 could safely and effectively treat a serious hormone imbalance (secondary hyperparathyroidism) in people with kidney failure who are on regular dialysis. It involved 498 participants in China and compared the drug's effects to a…
Matched conditions: SECONDARY HYPERPARATHYROIDISM
Phase: PHASE3 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC